- Title
- Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma
- Creator
- Hersey, Peter; Nguyen, T.; Farrelly, M.; Menzies, S.W.; Hirst, D.; Johnson, H.; Coventry, B.; Collins, S.
- Relation
- Cancer Immunology and Immunotherapy Vol. 54, no. 3, p. 208-218
- Publisher Link
- http://dx.doi.org/10.1007/s00262-004-0587-8
- Publisher
- Springer-Verlag
- Resource Type
- journal article
- Date
- 2005
- Description
- Previous studies in small groups of patients suggested that immunization of melanoma patients with peptide epitopes recognized by T cells could induce regression of melanoma. This approach was tested in 36 patients with stage IV melanoma. The (MHC class I-restricted) peptides were from gp100, MART-1, tyrosinase, and MAGE-3. The gp100 and MART-1 peptides had been modified to increase their immunogenicity. In half the patients (groups 3 and 4) the peptides were given in the adjuvant Montanide-ISA-720, and half the patients in both groups were given GM-CSF s.c. for 4 days following each injection. Treatment was well tolerated except for two severe erythematous responses to Montanide-ISA-720 and marked inflammatory responses at sites of GM-CSF administration in three patients. There were no objective clinical responses but stabilization of disease for periods from 3 to 12 months were seen in seven patients. Five of these were patients given the peptides in Montanide-ISA-720. Delayed-type hypersensitivity (DTH) skin test responses were also seen mainly in the patients given the peptides in Montanide-ISA-720. GM-CSF did not increase DTH responses in patients in the latter group but may have increased DTH responses in those not given peptides in Montanide-ISA-720. Inflammatory responses around s.c. metastases or regional lymph nodes were observed in two patients. These results suggest that the peptides are more effective when given in the adjuvant Montanide-ISA-720. Nevertheless, results from this study, together with those from a number of comparable studies, indicate that peptide vaccines are currently of minimal benefit to patients and support the need for ongoing development of new strategies in treatment of this disease. © Springer-Verlag 2004.
- Subject
- Adjuvants; Clinical responses; Melanoma; Peptide vaccines; T-cell responses
- Identifier
- uon:219
- Identifier
- http://hdl.handle.net/1959.13/25059
- Identifier
- ISSN:0340-7004
- Rights
- The original publication is available at www.springerlink.com
- Language
- eng
- Full Text
- Reviewed
- Hits: 4530
- Visitors: 5383
- Downloads: 547
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | SOURCE1 | Author final version | 100 KB | Adobe Acrobat PDF | View Details Download |